Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stability.

Ham-Karim HA, Ebili HO, Bradshaw K, Richman SD, Fadhil W, Domingo E, Tomlinson I, Ilyas M.

Pathol Res Pract. 2019 Jul;215(7):152445. doi: 10.1016/j.prp.2019.152445. Epub 2019 May 20.


Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.

Barrow P, Richman SD, Wallace AJ, Handley K, Hutchins GGA, Kerr D, Magill L, Evans DG, Gray R, Quirke P, Hill J.

Histopathology. 2019 Aug;75(2):236-246. doi: 10.1111/his.13895. Epub 2019 Jul 5.


Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer.

Ham-Karim HA, Ebili HO, Manger K, Fadhil W, Ahmad NS, Richman SD, Ilyas M.

Mol Diagn Ther. 2019 Jun;23(3):383-393. doi: 10.1007/s40291-019-00388-z.


Results of the UK NEQAS for Molecular Genetics reference sample analysis.

Richman SD, Fairley J, Hall JA, Nataraj N, Bhide M, Lau A, Norman KL, Deans ZC.

J Clin Pathol. 2018 Nov;71(11):989-994. doi: 10.1136/jclinpath-2018-205277. Epub 2018 Jul 20.


Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.

Alderdice M, Richman SD, Gollins S, Stewart JP, Hurt C, Adams R, McCorry AM, Roddy AC, Vimalachandran D, Isella C, Medico E, Maughan T, McArt DG, Lawler M, Dunne PD.

J Pathol. 2018 May;245(1):19-28. doi: 10.1002/path.5051. Epub 2018 Mar 25.


Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT.

JAMA Oncol. 2018 Apr 1;4(4):564-568. doi: 10.1001/jamaoncol.2017.3168.


Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.


RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016).

Richman SD, Fairley J, Butler R, Deans ZC.

Virchows Arch. 2017 Dec;471(6):721-729. doi: 10.1007/s00428-017-2162-7. Epub 2017 Jun 26.


Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.

Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G.

Ann Oncol. 2017 Mar 1;28(3):562-568. doi: 10.1093/annonc/mdw645.


How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.

Richman SD, Fairley J, Butler R, Deans ZC.

J Clin Pathol. 2017 Jan;70(1):58-62. doi: 10.1136/jclinpath-2016-203822. Epub 2016 Sep 28.


Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT.

JAMA Oncol. 2016 May 1;2(5):633-642. doi: 10.1001/jamaoncol.2015.6065.


HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P.

J Pathol. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29.


Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.

Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, Roberts H, James MD, Wozniak S, Bathia R, Pugh C, Maughan T, Jasani B; FOCUS4 Trial Management Group.

J Clin Pathol. 2016 Jan;69(1):35-41. doi: 10.1136/jclinpath-2015-203097. Epub 2015 Sep 7.


Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, de Haan AF, Punt CJ, Koopman M.

Clin Cancer Res. 2014 Oct 15;20(20):5322-30. doi: 10.1158/1078-0432.CCR-14-0332. Epub 2014 Aug 19.


A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT, Sampson JR, Seymour MT, Nichols LL, Kenny SL, Nelson A, Sampson CM, Hodgkinson E, Bridgewater JA, Furniss DL, Roy R, Pope MJ, Pope JK, Parmar M, Quirke P, Kaplan R.

Br J Cancer. 2014 Apr 29;110(9):2178-86. doi: 10.1038/bjc.2014.182. Epub 2014 Apr 17.


KRAS and BRAF mutations in Nigerian colorectal cancers.

Abdulkareem FB, Sanni LA, Richman SD, Chambers P, Hemmings G, Grabsch H, Quirke P, Elesha SO, Banjo AF, Atoyebi OA, Adesanya AA, Onyekwere CA, Ojukwu J, Anomneze EE, Rotimi O.

West Afr J Med. 2012 Jul-Sep;31(3):198-203.


KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.

Dijkstra JR, Heideman DA, Meijer GA, Boers JE, 't Hart NA, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira SV, Richman SD, Quirke P, Rouleau EL, Guinebretiere JM, Tejpar S, Biesmans B, van Krieken JH.

Virchows Arch. 2013 Jan;462(1):39-46. doi: 10.1007/s00428-012-1356-2. Epub 2012 Dec 15.


Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P.

Anal Cell Pathol (Amst). 2011;34(1-2):61-6. doi: 10.3233/ACP-2011-0005.


Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial.

Richman SD, Barrett JH, Seymour MT.

J Clin Oncol. 2011 Apr 20;29(12):e354-5; author reply e356-7. doi: 10.1200/JCO.2010.33.9556. Epub 2011 Mar 21. No abstract available.


What can the molecular pathologist offer for optimal decision making?

Richman SD, Hutchins GG, Seymour MT, Quirke P.

Ann Oncol. 2010 Oct;21 Suppl 7:vii123-9. doi: 10.1093/annonc/mdq379. Review.


KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P.

J Clin Oncol. 2009 Dec 10;27(35):5931-7. doi: 10.1200/JCO.2009.22.4295. Epub 2009 Nov 2.


Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT.

J Clin Oncol. 2009 Nov 20;27(33):5519-28. doi: 10.1200/JCO.2008.21.6283. Epub 2009 Oct 26.


Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT.

J Clin Oncol. 2008 Jun 1;26(16):2690-8. doi: 10.1200/JCO.2007.15.5580. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363.


Prediction of the response of colorectal cancer to systemic therapy.

Adlard JW, Richman SD, Seymour MT, Quirke P.

Lancet Oncol. 2002 Feb;3(2):75-82. Review.


Imaging: magnetic resonance imaging (MRI).

Jewel KL, Loigman BI, Mattern RF, Richman SD, Royer CC, Whelan CA.

J Med Soc N J. 1984 Oct;81(10):884-8. No abstract available.


Digital subtraction angiography.

Mattern RF, Jewel KL, Loigman BI, Richman SD, Royer CC, Whelan CA.

J Med Soc N J. 1983 Nov;80(11):969. No abstract available.


Superselective transcatheter embolization of traumatic renal hemorrhage.

Richman SD, Green WM, Kroll R, Casarella WJ.

AJR Am J Roentgenol. 1977 May;128(5):843-6.


Abnormal pulmonary gallium accumulation in P. carinii pneumonia.

Levenson SM, Warren RD, Richman SD, Johnston GS, Chabner BA.

Radiology. 1976 May;119(2):395-8.


Mediastinoscopy: a diagnostic aid in metastatic carcinoma of the breast.

Neifeld JP, Ingle JN, Tormey DC, Lippman ME, Richman SD, Michaelis LL.

Cancer. 1976 Apr;37(4):1973-6.


67Ga radionuclide imaging in Burkitt's lymphoma.

Richman SD, Appelbaum F, Levenson SM, Johnston GS, Ziegler JL.

Radiology. 1975 Dec;117(3 Pt 1):639-45.


67Ga accumulation in pulmonary lesions associated with bleomycin toxicity.

Richman SD, Levenson SM, Bunn PA, Flinn GS, Johnston GS, DeVita VT.

Cancer. 1975 Dec;36(6):1966-72.


Usefulness of gallium scintigraphy in primary and metastatic breast carcinoma.

Richman SD, Ingle JN, Leveson SM, Neifeld DC, Tormey DC, Jones AE, Johnston GS.

J Nucl Med. 1975 Nov;16(11):996-1001.


Breast scintigraphy with 99mTc-pertechnetate and 67Ga-citrate.

Richman SD, Brodey PA, Frankel RS, de Moss EV, Tormey DC, Johnston GS.

J Nucl Med. 1975 Apr;16(4):293-9.


Renal localization of gallium-67 citrate.

Frankel RS, Richman SD, Levenson SM, Johnston GS.

Radiology. 1975 Feb;114(2):393-7.


Radionuclide studies in Hodgkin's disease and lymphomas.

Richman SD, Levenson SM, Jones AE, Johnston GS.

Semin Nucl Med. 1975 Jan;5(1):103-8.


Supplemental Content

Loading ...
Support Center